Another previous study suggested that intravitreal antivascular endothelial growth factor (VEGF) agents can be considered as adjuncts to the traditional ablative treatment, with evident effect on resolution of macular edema and exudates secondary to Coats' disease [6]. The gene discussed is VEGFA; the disease is Coats disease.